ClinicalTrials.gg
CompletedNCT03835975Updated Feb 21, 2021Results posted

Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

A Phase 3 interventional study of 13vPnC and PPSV23 in Pneumococcal Disease, sponsored by Pfizer. Completed at 42 sites in 2 countries. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
875
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
8th of 19
875 · median 668
Started
2019
with 1 other
Phase 3
14 of 19
1 open now
Registered
3rd of 19
by date
Lead sponsor
16 of 19
Pfizer

Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 8th largest by enrollment, is one of 2 that started in 2019, is one of 14 in phase 3, and was the 3rd registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Pneumococcal 20-Valent Conjugate Vaccine

Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

This Phase 3 will describe the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine formulation in adults 65 years of age or older with prior pneumococcal vaccination

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adults 65 years of age or greater.
  2. Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of product.
  3. Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of .
  4. Male or female adults who meet 1 of the following:

    1. Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).
    2. Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).
    3. Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).

Exclusion criteria

Exclusion Criteria

  1. Serious chronic disorder including , severe (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
  2. History of microbiologically proven invasive disease caused by S pneumoniae.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
875 participants (actual)

Study arms

  • Active comparator
    13vPnC

    Pneumococcal conjugate vaccine

    Biological: 13vPnC

  • Active comparator
    PPSV23

    Pneumococcal polysaccharide vaccine

    Biological: PPSV23

  • Experimental
    20vPnC

    Pneumococcal conjugate vaccine

    Biological: 20vPnC

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions Within 10 Days After Vaccination

    Local reactions were recorded using an electronic diary (e-diary). Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

    Time frame: Within 10 days after vaccination

  2. Percentage of Participants With Systemic Events Within 7 Days After Vaccination

    Systemic events fever, fatigue, headache, muscle pain and joint pain were recorded by using an e-diary. Fever was defined as temperature \>=38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily routine activity).

    Time frame: Within 7 days after vaccination

  3. Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination

    An AE was any untoward medical occurrence in study participants who received study vaccine without regard to possibility of causal relationship with the treatment.

    Time frame: Within 1 month after vaccination

  4. Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination

    An SAE was any untoward medical occurrence at any dose that results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect or that is considered to be an important medical event.

    Time frame: Within 6 months after vaccination

  5. Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination

    An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects.

    Time frame: Within 6 months after vaccination

  6. Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) at 1 Month After Vaccination

    OPA GMTs were determined for serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. OPA titer was expressed as reciprocal of the highest serum dilution.

    Time frame: 1 month after vaccination

Secondary outcomes

  1. Pneumococcal OPA Geometric Mean Fold Rise (GMFR) From Before Vaccination to 1 Month After Vaccination

    OPA GMFR is the ratio of OPA GMTs, 1 month after vaccination to before vaccination. OPA GMFRs from before to 1 month after vaccination were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.

    Time frame: From before vaccination to 1 month after vaccination

  2. Percentage of Participants With >=4-Fold Rise in Pneumococcal OPA Titers From Before Vaccination to 1 Month After Vaccination

    Percentage of participants with a \>=4-fold rise in pneumococcal OPA titers from before vaccination to 1 month after vaccination were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.

    Time frame: From before vaccination to 1 month after vaccination

  3. Percentage of Participants With Pneumococcal OPA Titers >=Lower Limit of Quantitation (LLOQ) at 1 Month After Vaccination

    The percentage of participants with OPA titers \>=LLOQ at 1 month after vaccination were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.

    Time frame: 1 month after vaccination

07

Results

Posted Feb 21, 2021

Participant flow

Participant flow — Overall Study
MilestoneCohort A: 20vPnCCohort A: 13vPnCCohort B: 20vPnCCohort B: PPSV23Cohort C: 20vPnC
Started253122248127125
Vaccinated253122246127125
Safety population253122246127125
Evaluable immunogenicity population (for 20vpnc cohorts)24702430121
Completed250119245126125
Not completed33310
Withdrew: Lost to follow-up11000
Withdrew: No longer met eligibility criteria01000
Withdrew: Protocol violation11200
Withdrew: Withdrawal by subject10110

Outcome measures

PrimaryPercentage of Participants With Local Reactions Within 10 Days After Vaccination

Local reactions were recorded using an electronic diary (e-diary). Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

Time frame:
Within 10 days after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Local Reactions Within 10 Days After Vaccination
percentage of participantsCohort A: 20vPnCCohort A: 13vPnCCohort B: 20vPnCCohort B: PPSV23Cohort C: 20vPnC
Redness: Any7.9 (4.9 to 11.9)2.5 (0.5 to 7.1)8.6 (5.4 to 12.8)12.7 (7.4 to 19.8)4.8 (1.8 to 10.2)
Redness: Mild3.6 (1.6 to 6.6)1.7 (0.2 to 5.8)2.9 (1.2 to 5.8)4.8 (1.8 to 10.1)1.6 (0.2 to 5.7)
Redness: Moderate3.2 (1.4 to 6.1)0.8 (0.0 to 4.5)5.3 (2.9 to 8.9)7.1 (3.3 to 13.1)3.2 (0.9 to 8.0)
Redness: Severe1.2 (0.2 to 3.4)0 (0.0 to 3.0)0.4 (0.0 to 2.3)0.8 (0.0 to 4.3)0 (0.0 to 2.9)
Swelling: Any9.9 (6.5 to 14.2)6.6 (2.9 to 12.6)9.4 (6.0 to 13.8)14.3 (8.7 to 21.6)4.0 (1.3 to 9.1)
Swelling: Mild5.1 (2.8 to 8.6)6.6 (2.9 to 12.6)5.7 (3.2 to 9.4)6.3 (2.8 to 12.1)1.6 (0.2 to 5.7)
Swelling: Moderate3.6 (1.6 to 6.6)0 (0.0 to 3.0)3.7 (1.7 to 6.9)7.1 (3.3 to 13.1)2.4 (0.5 to 6.9)
Swelling: Severe1.2 (0.2 to 3.4)0 (0.0 to 3.0)0 (0.0 to 1.5)0.8 (0.0 to 4.3)0 (0.0 to 2.9)
Pain at the injection site: Any50.2 (43.9 to 56.5)43.0 (34.0 to 52.3)61.2 (54.8 to 67.4)56.3 (47.2 to 65.2)52.8 (43.7 to 61.8)
Pain at the injection site: Mild45.8 (39.6 to 52.2)38.8 (30.1 to 48.1)54.7 (48.2 to 61.0)40.5 (31.8 to 49.6)47.2 (38.2 to 56.3)
Pain at the injection site: Moderate4.3 (2.2 to 7.6)3.3 (0.9 to 8.2)6.1 (3.5 to 9.9)14.3 (8.7 to 21.6)5.6 (2.3 to 11.2)
Pain at the injection site: Severe0 (0.0 to 1.4)0.8 (0.0 to 4.5)0.4 (0.0 to 2.3)1.6 (0.2 to 5.6)0 (0.0 to 2.9)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination

Systemic events fever, fatigue, headache, muscle pain and joint pain were recorded by using an e-diary. Fever was defined as temperature \>=38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily routine activity).

Time frame:
Within 7 days after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination
percentage of participantsCohort A: 20vPnCCohort A: 13vPnCCohort B: 20vPnCCohort B: PPSV23Cohort C: 20vPnC
Fever: >=38.0 degree C0.8 (0.1 to 2.8)0 (0.0 to 3.0)0 (0.0 to 1.5)1.6 (0.2 to 5.6)0 (0.0 to 2.9)
Fever: >=38.0 degree C to 38.4 degree C0.8 (0.1 to 2.8)0 (0.0 to 3.0)0 (0.0 to 1.5)0.8 (0.0 to 4.3)0 (0.0 to 2.9)
Fever: >38.4 degree C to 38.9 degree C0 (0.0 to 1.4)0 (0.0 to 3.0)0 (0.0 to 1.5)0.8 (0.0 to 4.3)0 (0.0 to 2.9)
Fever: >38.9 degree C to 40.0 degree C0 (0.0 to 1.4)0 (0.0 to 3.0)0 (0.0 to 1.5)0 (0.0 to 2.9)0 (0.0 to 2.9)
Fever: >40.0 degree C0 (0.0 to 1.4)0 (0.0 to 3.0)0 (0.0 to 1.5)0 (0.0 to 2.9)0 (0.0 to 2.9)
Fatigue: Any28.9 (23.4 to 34.9)22.3 (15.2 to 30.8)31.0 (25.3 to 37.2)33.3 (25.2 to 42.3)32.8 (24.7 to 41.8)
Fatigue: Mild17.8 (13.3 to 23.1)9.9 (5.2 to 16.7)19.6 (14.8 to 25.1)19.8 (13.3 to 27.9)19.2 (12.7 to 27.2)
Fatigue: Moderate11.1 (7.5 to 15.6)9.9 (5.2 to 16.7)10.2 (6.7 to 14.7)13.5 (8.1 to 20.7)12.0 (6.9 to 19.0)
Fatigue: Severe0 (0.0 to 1.4)2.5 (0.5 to 7.1)1.2 (0.3 to 3.5)0 (0.0 to 2.9)1.6 (0.2 to 5.7)
Headache: Any17.8 (13.3 to 23.1)18.2 (11.8 to 26.2)13.5 (9.5 to 18.4)21.4 (14.6 to 29.6)19.2 (12.7 to 27.2)
Headache: Mild12.6 (8.8 to 17.4)12.4 (7.1 to 19.6)9.8 (6.4 to 14.2)20.6 (13.9 to 28.8)12.8 (7.5 to 20.0)
Headache: Moderate4.7 (2.5 to 8.1)5.8 (2.4 to 11.6)3.7 (1.7 to 6.9)0.8 (0.0 to 4.3)5.6 (2.3 to 11.2)
Headache: Severe0.4 (0.0 to 2.2)0 (0.0 to 3.0)0 (0.0 to 1.5)0 (0.0 to 2.9)0.8 (0.0 to 4.4)
Muscle Pain: Any32.0 (26.3 to 38.1)31.4 (23.3 to 40.5)33.9 (28.0 to 40.2)46.0 (37.1 to 55.1)37.6 (29.1 to 46.7)
Muscle Pain: Mild26.1 (20.8 to 32.0)24.0 (16.7 to 32.6)25.3 (20.0 to 31.2)31.7 (23.7 to 40.6)28.0 (20.3 to 36.7)
Muscle Pain: Moderate5.5 (3.1 to 9.1)5.0 (1.8 to 10.5)8.6 (5.4 to 12.8)11.9 (6.8 to 18.9)8.8 (4.5 to 15.2)
Muscle Pain: Severe0.4 (0.0 to 2.2)2.5 (0.5 to 7.1)0 (0.0 to 1.5)2.4 (0.5 to 6.8)0.8 (0.0 to 4.4)
Joint Pain: Any6.7 (4.0 to 10.5)10.7 (5.8 to 17.7)11.8 (8.1 to 16.6)15.9 (10.0 to 23.4)16.8 (10.7 to 24.5)
Joint Pain: Mild4.7 (2.5 to 8.1)5.0 (1.8 to 10.5)7.8 (4.7 to 11.8)10.3 (5.6 to 17.0)12.8 (7.5 to 20.0)
Joint Pain: Moderate2.0 (0.6 to 4.6)5.0 (1.8 to 10.5)4.1 (2.0 to 7.4)5.6 (2.3 to 11.1)4.0 (1.3 to 9.1)
Joint Pain: Severe0 (0.0 to 1.4)0.8 (0.0 to 4.5)0 (0.0 to 1.5)0 (0.0 to 2.9)0 (0.0 to 2.9)
PrimaryPercentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination

An AE was any untoward medical occurrence in study participants who received study vaccine without regard to possibility of causal relationship with the treatment.

Time frame:
Within 1 month after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination
percentage of participantsCohort A: 20vPnCCohort A: 13vPnCCohort B: 20vPnCCohort B: PPSV23Cohort C: 20vPnC
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination7.5 (4.6 to 11.5)9.0 (4.6 to 15.6)4.9 (2.5 to 8.4)11.0 (6.2 to 17.8)10.4 (5.7 to 17.1)
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination

An SAE was any untoward medical occurrence at any dose that results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect or that is considered to be an important medical event.

Time frame:
Within 6 months after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination
percentage of participantsCohort A: 20vPnCCohort A: 13vPnCCohort B: 20vPnCCohort B: PPSV23Cohort C: 20vPnC
Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination0.8 (0.1 to 2.8)1.6 (0.2 to 5.8)2.4 (0.9 to 5.2)1.6 (0.2 to 5.6)1.6 (0.2 to 5.7)
PrimaryPercentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination

An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects.

Time frame:
Within 6 months after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination
percentage of participantsCohort A: 20vPnCCohort A: 13vPnCCohort B: 20vPnCCohort B: PPSV23Cohort C: 20vPnC
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination2.0 (0.6 to 4.6)0.8 (0.0 to 4.5)2.8 (1.2 to 5.8)2.4 (0.5 to 6.7)4.0 (1.3 to 9.1)
PrimaryPneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) at 1 Month After Vaccination

OPA GMTs were determined for serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. OPA titer was expressed as reciprocal of the highest serum dilution.

Time frame:
1 month after vaccination
Reported as:
Geometric mean · titer
Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) at 1 Month After Vaccination
titerCohort A: 20vPnCCohort B: 20vPnCCohort C: 20vPnC
Serotype 150.8 (41.6 to 62.0)115.3 (96.3 to 137.9)82.1 (61.2 to 110.1)
Serotype 331.1 (26.7 to 36.1)54.3 (46.9 to 62.8)39.3 (32.0 to 48.2)
Serotype 4149.9 (118.2 to 190.1)334.9 (273.8 to 409.5)193.7 (143.2 to 262.0)
Serotype 562.8 (52.7 to 74.9)87.3 (73.2 to 104.2)83.5 (64.8 to 107.6)
Serotype 6A748.7 (576.7 to 972.0)1080.9 (880.2 to 1327.4)1085.3 (796.9 to 1478.1)
Serotype 6B727.3 (573.6 to 922.1)1159.4 (950.7 to 1413.8)1033.3 (754.6 to 1414.8)
Serotype 7F378.1 (316.4 to 451.9)555.4 (466.8 to 660.9)345.8 (277.0 to 431.7)
Serotype 9V550.3 (454.0 to 666.9)1085.0 (893.5 to 1317.5)723.4 (558.1 to 937.6)
Serotype 14391.2 (314.6 to 486.3)664.9 (554.1 to 797.9)580.5 (433.7 to 777.0)
Serotype 18C551.9 (445.1 to 684.4)845.9 (692.5 to 1033.1)621.2 (469.9 to 821.3)
Serotype 19A238.6 (197.5 to 288.4)365.1 (303.0 to 440.0)340.6 (264.1 to 439.2)
Serotype 19F159.0 (131.4 to 192.3)242.3 (199.4 to 294.3)217.7 (168.1 to 281.8)
Serotype 23F151.6 (115.3 to 199.3)450.2 (357.8 to 566.4)292.6 (203.6 to 420.5)
Serotype 8211.9 (172.0 to 261.0)602.9 (482.9 to 752.8)293.8 (220.0 to 392.4)
Serotype 10A1012.1 (806.7 to 1269.8)2005.4 (1586.0 to 2535.7)1580.3 (1175.9 to 2123.8)
Serotype 11A1473.2 (1192.4 to 1820.2)1908.2 (1541.5 to 2362.2)1566.6 (1140.7 to 2151.4)
Serotype 12F1054.5 (822.0 to 1352.7)1763.4 (1371.8 to 2266.7)1401.2 (1001.8 to 1959.7)
Serotype 15B647.1 (490.8 to 853.1)1479.5 (1093.0 to 2002.8)1066.9 (721.3 to 1578.1)
Serotype 22F1772.8 (1354.7 to 2319.8)4156.5 (3243.8 to 5326.2)2717.8 (1978.4 to 3733.4)
Serotype 33F2026.2 (1684.3 to 2437.4)3174.9 (2579.1 to 3908.3)2182.9 (1638.6 to 2907.8)
SecondaryPneumococcal OPA Geometric Mean Fold Rise (GMFR) From Before Vaccination to 1 Month After Vaccination

OPA GMFR is the ratio of OPA GMTs, 1 month after vaccination to before vaccination. OPA GMFRs from before to 1 month after vaccination were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.

Time frame:
From before vaccination to 1 month after vaccination
Reported as:
Geometric mean · fold rise
Pneumococcal OPA Geometric Mean Fold Rise (GMFR) From Before Vaccination to 1 Month After Vaccination
fold riseCohort A: 20vPnCCohort B: 20vPnCCohort C: 20vPnC
Serotype 12.2 (1.9 to 2.5)3.4 (2.9 to 4.1)2.0 (1.7 to 2.4)
Serotype 32.4 (2.1 to 2.8)3.5 (3.1 to 4.1)1.9 (1.6 to 2.3)
Serotype 44.9 (3.9 to 6.1)5.0 (4.1 to 6.2)2.4 (1.9 to 3.1)
Serotype 52.3 (2.0 to 2.6)2.3 (2.0 to 2.6)1.8 (1.5 to 2.0)
Serotype 6A12.6 (9.5 to 16.7)8.3 (6.6 to 10.4)6.5 (4.7 to 9.1)
Serotype 6B6.6 (5.2 to 8.4)6.7 (5.4 to 8.3)4.0 (3.0 to 5.2)
Serotype 7F2.3 (1.9 to 2.7)2.6 (2.2 to 3.0)1.6 (1.4 to 2.0)
Serotype 9V2.4 (2.1 to 2.9)3.1 (2.6 to 3.6)2.1 (1.7 to 2.6)
Serotype 141.8 (1.5 to 2.1)2.3 (1.9 to 2.8)1.7 (1.4 to 2.1)
Serotype 18C3.2 (2.5 to 3.9)3.9 (3.2 to 4.8)2.2 (1.8 to 2.7)
Serotype 19A2.9 (2.4 to 3.4)2.9 (2.4 to 3.4)1.9 (1.6 to 2.2)
Serotype 19F2.6 (2.2 to 3.1)2.7 (2.3 to 3.2)1.9 (1.5 to 2.3)
Serotype 23F6.6 (5.1 to 8.5)9.3 (7.4 to 11.8)4.5 (3.4 to 6.0)
Serotype 83.6 (2.9 to 4.4)22.5 (17.2 to 29.4)2.1 (1.6 to 2.8)
Serotype 10A4.5 (3.5 to 5.7)14.4 (10.9 to 19.0)4.4 (3.3 to 6.0)
Serotype 11A2.5 (2.0 to 3.2)6.7 (5.0 to 9.0)3.1 (2.2 to 4.4)
Serotype 12F7.2 (5.5 to 9.5)31.7 (23.1 to 43.4)3.8 (2.7 to 5.5)
Serotype 15B4.3 (3.3 to 5.7)18.9 (13.0 to 27.4)4.8 (3.1 to 7.5)
Serotype 22F11.1 (8.0 to 15.3)66.9 (46.5 to 96.4)9.8 (6.2 to 15.6)
Serotype 33F1.8 (1.5 to 2.2)5.4 (4.2 to 6.8)1.8 (1.4 to 2.2)
SecondaryPercentage of Participants With >=4-Fold Rise in Pneumococcal OPA Titers From Before Vaccination to 1 Month After Vaccination

Percentage of participants with a \>=4-fold rise in pneumococcal OPA titers from before vaccination to 1 month after vaccination were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.

Time frame:
From before vaccination to 1 month after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With >=4-Fold Rise in Pneumococcal OPA Titers From Before Vaccination to 1 Month After Vaccination
percentage of participantsCohort A: 20vPnCCohort B: 20vPnCCohort C: 20vPnC
Serotype 122.9 (17.8 to 28.6)40.3 (34.1 to 46.8)20.8 (14.0 to 29.2)
Serotype 329.6 (24.0 to 35.8)41.3 (35.0 to 47.8)18.5 (12.0 to 26.6)
Serotype 441.1 (34.7 to 47.8)41.3 (34.9 to 47.9)25.2 (17.6 to 34.2)
Serotype 525.7 (20.3 to 31.7)27.2 (21.7 to 33.2)15.8 (9.8 to 23.6)
Serotype 6A61.5 (55.0 to 67.7)56.4 (49.8 to 62.9)44.9 (35.7 to 54.3)
Serotype 6B53.4 (46.8 to 59.8)55.0 (48.5 to 61.5)35.3 (26.8 to 44.6)
Serotype 7F26.2 (20.7 to 32.3)30.3 (24.6 to 36.5)14.3 (8.5 to 21.9)
Serotype 9V28.3 (22.5 to 34.7)36.0 (29.7 to 42.6)20.2 (13.2 to 28.7)
Serotype 1415.7 (11.3 to 21.0)24.9 (19.5 to 30.9)16.0 (9.9 to 23.8)
Serotype 18C29.4 (23.8 to 35.5)38.3 (32.2 to 44.8)17.6 (11.3 to 25.7)
Serotype 19A29.7 (24.0 to 35.9)29.3 (23.6 to 35.5)15.4 (9.4 to 23.2)
Serotype 19F29.2 (23.6 to 35.4)32.8 (26.9 to 39.1)16.9 (10.7 to 25.0)
Serotype 23F49.6 (43.1 to 56.1)58.7 (52.2 to 64.9)42.9 (33.8 to 52.3)
Serotype 839.9 (33.4 to 46.7)72.6 (66.2 to 78.4)30.7 (21.9 to 40.7)
Serotype 10A45.5 (38.4 to 52.7)70.9 (64.0 to 77.1)44.0 (34.5 to 53.9)
Serotype 11A30.4 (23.9 to 37.6)54.6 (47.1 to 62.0)35.2 (25.4 to 45.9)
Serotype 12F51.4 (44.4 to 58.4)76.5 (70.0 to 82.2)40.8 (31.2 to 50.9)
Serotype 15B37.4 (30.9 to 44.3)66.3 (59.0 to 73.1)38.4 (28.8 to 48.7)
Serotype 22F57.0 (50.0 to 63.8)83.2 (77.2 to 88.2)54.8 (44.7 to 64.6)
Serotype 33F18.7 (13.6 to 24.8)53.6 (46.3 to 60.7)19.2 (12.0 to 28.3)
SecondaryPercentage of Participants With Pneumococcal OPA Titers >=Lower Limit of Quantitation (LLOQ) at 1 Month After Vaccination

The percentage of participants with OPA titers \>=LLOQ at 1 month after vaccination were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.

Time frame:
1 month after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Pneumococcal OPA Titers >=Lower Limit of Quantitation (LLOQ) at 1 Month After Vaccination
percentage of participantsCohort A: 20vPnCCohort B: 20vPnCCohort C: 20vPnC
Serotype 165.4 (59.1 to 71.4)87.7 (82.8 to 91.5)77.5 (69.0 to 84.6)
Serotype 376.1 (70.3 to 81.3)90.5 (86.1 to 93.9)87.4 (80.1 to 92.8)
Serotype 476.7 (70.8 to 81.9)91.7 (87.5 to 94.9)87.1 (79.6 to 92.6)
Serotype 564.8 (58.4 to 70.7)74.9 (69.0 to 80.2)72.5 (63.6 to 80.3)
Serotype 6A84.3 (79.1 to 88.6)93.8 (89.9 to 96.5)90.9 (84.3 to 95.4)
Serotype 6B86.8 (81.9 to 90.8)93.8 (89.9 to 96.5)91.7 (85.3 to 96.0)
Serotype 7F74.2 (68.1 to 79.6)84.8 (79.6 to 89.0)79.2 (70.8 to 86.0)
Serotype 9V76.8 (70.9 to 81.9)89.5 (84.8 to 93.1)85.5 (77.8 to 91.3)
Serotype 1485.8 (80.8 to 90.0)95.0 (91.5 to 97.4)93.3 (87.2 to 97.1)
Serotype 18C91.8 (87.7 to 94.9)96.3 (93.0 to 98.3)95.8 (90.5 to 98.6)
Serotype 19A93.8 (90.0 to 96.5)95.9 (92.5 to 98.0)98.3 (94.1 to 99.8)
Serotype 19F71.7 (65.6 to 77.3)84.3 (79.1 to 88.6)84.7 (77.0 to 90.7)
Serotype 23F76.3 (70.5 to 81.5)93.8 (90.0 to 96.5)87.5 (80.2 to 92.8)
Serotype 885.2 (80.0 to 89.5)94.7 (90.9 to 97.2)90.8 (83.8 to 95.5)
Serotype 10A92.2 (87.9 to 95.4)95.7 (92.0 to 98.0)96.4 (91.0 to 99.0)
Serotype 11A91.2 (86.6 to 94.6)94.7 (90.6 to 97.3)89.2 (81.5 to 94.5)
Serotype 12F87.9 (82.9 to 91.9)93.0 (88.7 to 96.0)91.8 (85.0 to 96.2)
Serotype 15B84.9 (79.5 to 89.3)91.0 (86.2 to 94.6)90.0 (82.8 to 94.9)
Serotype 22F94.0 (90.0 to 96.8)99.0 (96.5 to 99.9)98.1 (93.5 to 99.8)
Serotype 33F88.9 (83.9 to 92.7)91.8 (87.2 to 95.2)87.4 (79.4 to 93.1)

Adverse events

Collected over Other AEs: local reactions within 10 days after vaccination, systemic events: within 7 days after vaccination (systematic assessment), non serious AEs up to 1 month after Vaccination; SAEs: up to 6 months after vaccination. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: 20vPnC0/253 (0%)2/253 (0.8%)173/253 (68.4%)
Cohort A: 13vPnC0/122 (0%)2/122 (1.6%)69/122 (56.6%)
Cohort B: 20vPnC0/246 (0%)6/246 (2.4%)178/246 (72.4%)
Cohort B: PPSV230/127 (0%)2/127 (1.6%)96/127 (75.6%)
Cohort C: 20vPnC0/125 (0%)2/125 (1.6%)86/125 (68.8%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventCohort A: 20vPnCCohort A: 13vPnCCohort B: 20vPnCCohort B: PPSV23Cohort C: 20vPnC
CholecystitisHepatobiliary disorders0/2531/1220/2460/1270/125
Blood pressure decreasedInvestigations0/2531/1220/2460/1270/125
SyncopeNervous system disorders0/2530/1222/2460/1270/125
PneumoniaInfections and infestations0/2530/1220/2460/1271/125
OsteoarthritisMusculoskeletal and connective tissue disorders0/2530/1220/2460/1271/125
DysphagiaGastrointestinal disorders0/2530/1220/2461/1270/125
AppendicitisInfections and infestations0/2530/1220/2461/1270/125
Clostridium difficile colitisInfections and infestations0/2530/1220/2461/1270/125
DehydrationMetabolism and nutrition disorders0/2530/1220/2461/1270/125
Acute myocardial infarctionCardiac disorders0/2530/1221/2460/1270/125
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCohort A: 20vPnCCohort A: 13vPnCCohort B: 20vPnCCohort B: PPSV23Cohort C: 20vPnC
Injection site pain (PAIN)General disorders127/25352/122150/24671/12766/125
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders81/25338/12283/24658/12747/125
Fatigue (FATIGUE)General disorders73/25327/12276/24642/12741/125
Headache (HEADACHE)Nervous system disorders45/25322/12233/24627/12724/125
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders17/25313/12229/24620/12721/125
Injection site swelling (SWELLING)General disorders25/2538/12223/24618/1275/125
Injection site erythema (REDNESS)General disorders20/2533/12221/24616/1276/125
Urinary tract infectionInfections and infestations0/2532/1220/2460/1270/125
Pyrexia (FEVER)General disorders0/2530/1220/2462/1270/125
DizzinessNervous system disorders0/2530/1221/2462/1270/125

Baseline characteristics

All randomized population.

Age, Continuous
Age, Continuous(years)Cohort A: 20vPnCCohort A: 13vPnCCohort B: 20vPnCCohort B: PPSV23Cohort C: 20vPnCTotal
Mean69.6 ± 3.8870.2 ± 4.0970.7 ± 5.7070.6 ± 5.7370.8 ± 4.2670.3 ± 4.84
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: 20vPnCCohort A: 13vPnCCohort B: 20vPnCCohort B: PPSV23Cohort C: 20vPnCTotal
Female140641406865477
Male113581085960398
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A: 20vPnCCohort A: 13vPnCCohort B: 20vPnCCohort B: PPSV23Cohort C: 20vPnCTotal
Hispanic or Latino4361216
Not Hispanic or Latino247117233122113832
Unknown or Not Reported22941027
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A: 20vPnCCohort A: 13vPnCCohort B: 20vPnCCohort B: PPSV23Cohort C: 20vPnCTotal
American Indian or Alaska Native101002
Asian120205
Native Hawaiian or Other Pacific Islander011103
Black or African American158146447
White236110228118117809
More than one race001034
Unknown or Not Reported013015
08

Study locations

42 sites
  • Coastal Clinical Research, Inc.
    Mobile, Alabama 36608, United States
  • East Valley Gastroenterology and Hepatology Associates
    Chandler, Arizona 85224, United States
  • The Pain Center of Arizona
    Peoria, Arizona 85381, United States
  • HOPE Research Institute
    Phoenix, Arizona 85018, United States
  • The Pain Center of Arizona
    Phoenix, Arizona 85018, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Clinical Research Consulting, LLC
    Milford, Connecticut 06460, United States
  • Optimal Research, LLC
    Melbourne, Florida 32934, United States
  • Synexus Clinical Research US, Inc
    The Villages, Florida 32162, United States
  • Meridian Clinical Research, LLC
    Savannah, Georgia 31406, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67205, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • MedPharmics, LLC
    Metairie, Louisiana 70006, United States
  • Meridian Clinical Research, LLC
    Rockville, Maryland 20854, United States
  • Meridian Clinical Research, LLC
    Norfolk, Nebraska 68701, United States
  • MedPharmics, LLC
    Albuquerque, New Mexico 87102, United States
  • Carolina Institute for Clinical Research
    Fayetteville, North Carolina 28304, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Sterling Research Group, Ltd.
    Cincinnati, Ohio 45246, United States
  • Prestige Clinical Research
    Franklin, Ohio 45005, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Kaiser Permanente Center For Health Research
    Portland, Oregon 97227, United States
  • Columbia Research Group, Inc.
    Portland, Oregon 97239, United States
  • Medical Research South, LLC
    Goose Creek, South Carolina 29445, United States
  • Ventavia Research Group
    Keller, Texas 76248, United States
  • J. Lewis Research Inc. / Foothill Family Clinic Draper
    Draper, Utah 84020, United States
  • J. Lewis Research, Inc. - Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
  • J. Lewis Research, Inc. / Jordan River Family Medicine
    South Jordan, Utah 84095, United States
  • Kaiser Permanente Washington Health Research Institute
    Seattle, Washington 98101, United States
  • PharmaSite
    Malmo, Skane 21152, Sweden
  • Ladulaas Kliniska Studier
    Boras, 50630, Sweden
  • Infektionskliniken
    Eskilstuna, 63188, Sweden
  • CTC Gothia Forum
    Goteborg, 413 45, Sweden
  • ProbarE i Lund
    Lund, 22222, Sweden
  • Avdelningen for Kliniska Provningar
    Orebro, 703 62, Sweden
  • Karolinska Trial Alliance, KTA Prim
    Stockholm, 11361, Sweden
  • Akardo Med Site
    Stockholm, 11446, Sweden
09

References and documents

Publications

  • Cannon K, Elder C, Young M, Scott DA, Scully IL, Baugher G, Peng Y, Jansen KU, Gruber WC, Watson W. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults >/=65 years of age with different prior pneumococcal vaccination. Vaccine. 2021 Dec 17;39(51):7494-7502. doi: 10.1016/j.vaccine.2021.10.032. Epub 2021 Nov 25. PubMed 34839993 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Feb 2020, 12 months.

Results were first posted in Feb 2021, 1 year after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 12 months is close to that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2019
First posted
Feb 11, 2019
StartActual
Feb 12, 2019
Primary completionActual
Feb 12, 2020
CompletionActual
Feb 12, 2020
Results first posted
Feb 21, 2021
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03835975
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 11, 2019
Start date
Feb 12, 2019
Primary completion
Feb 12, 2020
Completion
Feb 12, 2020
Results posted
Feb 21, 2021
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion